Derivative exercise or conversion — not an open-market buy.
Loading…
Reporting person on SEC Form 4
George Fennell
George Fennell is Executive Vice President at Idexx Laboratories. OQRO lists 27 transactions filed with the SEC under this name, the latest on Jun 2, 2026, each linked to the official Form 4.
Executive Vice President
Disclosures on record
27
Companies involved
1
Disclosure history
Derivative exercise or conversion — not an open-market buy.
Routine share withholding; mechanical by default.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Routine share withholding; mechanical by default.
Officer sold
~$1.82MReported value · 2,809 sh @ $649.2599
Stock since the trade -18.5% · S&P 500 +11.9% · to Oct 5
Idexx Laboratories's Executive Vice President sold $1.82M of Idexx Laboratories shares. Nobody planned it ahead of time.
Officer sold
~$1.8MReported value · 2,782 sh @ $646.2259
Stock since the trade -18.5% · S&P 500 +11.9% · to Oct 5
Idexx Laboratories's Executive Vice President sold $1.8M of Idexx Laboratories shares. Nobody planned it ahead of time.
Officer sold
~$1.39MReported value · 2,161 sh @ $645.2512
Stock since the trade -18.5% · S&P 500 +11.9% · to Oct 5
Idexx Laboratories's Executive Vice President sold $1.39M of Idexx Laboratories shares. Nobody planned it ahead of time.
Officer sold
~$727KReported value · 1,130 sh @ $642.9974
Stock since the trade -18.5% · S&P 500 +11.9% · to Oct 5
Idexx Laboratories's Executive Vice President sold $727K of Idexx Laboratories shares. Nobody planned it ahead of time.
Officer sold
~$686KReported value · 1,060 sh @ $647.2066
Stock since the trade -18.5% · S&P 500 +11.9% · to Oct 5
Idexx Laboratories's Executive Vice President sold $686K of Idexx Laboratories shares. Nobody planned it ahead of time.
Officer sold
~$627KReported value · 966 sh @ $648.7792
Stock since the trade -18.5% · S&P 500 +11.9% · to Oct 5
Idexx Laboratories's Executive Vice President sold $627K of Idexx Laboratories shares. Nobody planned it ahead of time.
Officer sold
~$256KReported value · 397 sh @ $644.016
Stock since the trade -18.5% · S&P 500 +11.9% · to Oct 5
Idexx Laboratories's Executive Vice President sold $256K of Idexx Laboratories shares. Nobody planned it ahead of time.
Officer sold
~$26KReported value · 40 sh @ $650.32
Stock since the trade -18.5% · S&P 500 +11.9% · to Oct 5
Idexx Laboratories's Executive Vice President sold $26K of Idexx Laboratories shares. Nobody planned it ahead of time.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.